Eidolon develops next‑generation cancer immunotherapies that use engineered microbial proteins to turn immunologically “cold” tumors into “hot” ones, enhancing anti‑tumor immune responses while limiting chronic inflammation. Their platform aims to precisely and rapidly eliminate cancer cells, offering a targeted approach to boost tumour immunity without the side effects of conventional treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Many solid tumors create an immunosuppressive microenvironment that prevents immune cells from recognizing and destroying cancer cells, rendering checkpoint inhibitor therapies ineffective for a large patient population.
Solution
Eidolon Therapeutics engineers microbial proteins that, when delivered to tumors, reprogram the local immune landscape from a “cold” suppressive state to a “hot” immune‑responsive state. The engineered proteins activate innate and adaptive immune pathways, promoting rapid and precise tumor cell elimination while limiting chronic inflammation. By integrating microbial genome mining, live‑cell imaging, and AI‑driven design, Eidolon creates a pipeline for generating highly specific protein therapeutics tailored to diverse cancer types. The approach aims to extend the benefits of immunotherapy to patients whose tumors are resistant to existing checkpoint inhibitors.
Target Audience
Primary customers are oncology pharmaceutical companies and clinical research organizations developing immunotherapies for solid tumors that are non‑responsive to current checkpoint inhibitors.
Features
- Engineered microbial proteins designed to activate tumor‑infiltrating immune cells and convert immunosuppressive microenvironments into immunogenic ones
- AI‑guided protein design pipeline that accelerates discovery and optimization of therapeutic candidates
- Live‑cell imaging platform for real‑time assessment of protein‑mediated immune activation and tumor cell killing
- Modular platform enabling rapid adaptation of protein therapeutics to multiple cancer indications and stages
- Built‑in mechanisms to minimize chronic inflammation and off‑target immune activation